Boehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment for patients with schizophrenia.
A sublingual film for acute agitation in schizophrenia and bipolar disorder from BioXcel has blockbuster potential that could pose a threat to an inhaled rival from Galen, according to anal
Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department.
